Efficacy News and Research

RSS

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

FLASH radiotherapy could revolutionize future tumor treatments

It could become a breakthrough for future tumor treatments with heavy ions and pave new ways: In the current experiment period FAIR-Phase 0, the GSI Helmholtzzentrum für Schwerionenforschung and the future accelerator center FAIR succeeded in performing a carbon ion FLASH experiment for the first time.

21 Jun 2021

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

21 Jun 2021

FDA approves oral pellets to treat children with venous thromboembolism

Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days.

21 Jun 2021

Study reviews natural drug candidates for potential treatment of COVID-19

A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.

21 Jun 2021

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

Researchers from the German Center for Infection Research at Charité - Universitätsmedizin Berlin and the University of Bonn have examined the way in which SARS-CoV-2 reprograms the metabolism of the host cell in order to gain an overall advantage.

21 Jun 2021

Can a prior rhinovirus infection protect against COVID-19?

Researchers at the Yale School of Medicine found that rhinovirus accelerates interferon-stimulated genes.

21 Jun 2021

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.

21 Jun 2021

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Recently, researchers discuss their development of cell membrane-based nanoparticles that successfully delivered dexamethasone directly to inflamed lung cells.

21 Jun 2021

Novel vaccine based on mRNA technology protects against malaria in animal models

Scientists from the Walter Reed Army Institute of Research and Naval Medical Research Center partnered with researchers at the University of Pennsylvania and Acuitas Therapeutics to develop a novel vaccine based on mRNA technology that protects against malaria in animal models, publishing their findings in npj Vaccines.

18 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

A new study, released as a preprint on bioRxiv* server, shows that a combination of the biological interferon-α and the small molecule nafamostat are effective against SARS-CoV-2 infection in vitro, as well as in vivo.

18 Jun 2021

COVID-19 outbreak in Mauritius dominated by new SARS-CoV-2 variant B.1.1.318

Underlining the key role of genomic surveillance in keeping tabs on the spread of SARS-CoV-2, a new medRxiv* preprint shows how a new variant called B.1.1.318 rose to dominance in the small island country of Mauritius, in the Indian Ocean.

18 Jun 2021

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

A new study, released as a preprint on the bioRxiv* server, reveals the high neutralizing efficacy of hyperimmune horse serum against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could prove, if validated, to be a more affordable yet potent therapeutic in reducing the morbidity and mortality caused by this virus.

18 Jun 2021

New computational model simulates the spread and impact of COVID-19 virus

The emergence and rapid spread of novel Covid-19 coronavirus in early 2020 spurred numerous accelerated efforts to develop a vaccine. At the time it was not clear how effective these vaccines needed to be to slow or stop the pandemic.

18 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

The SARS-CoV-2 virus and its vaccines pose unique challenges

Iranian researchers recently provided a review of the attempts made to develop safe SARS-CoV-2 vaccines. The researchers outlined potential challenges and concerns, including disease enhancement, virus mutation, and public acceptability. Their work is published in the journal Immunological Investigations.

18 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

Efficacy News and Research

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

FLASH radiotherapy could revolutionize future tumor treatments

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

FDA approves oral pellets to treat children with venous thromboembolism

Study reviews natural drug candidates for potential treatment of COVID-19

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

Can a prior rhinovirus infection protect against COVID-19?

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Novel vaccine based on mRNA technology protects against malaria in animal models

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

COVID-19 outbreak in Mauritius dominated by new SARS-CoV-2 variant B.1.1.318

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

New computational model simulates the spread and impact of COVID-19 virus

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

The SARS-CoV-2 virus and its vaccines pose unique challenges

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News